Physician profile
Mark C Goldberg
NPI 1700804366
$11,879.94
in general payments reported to CMS, 2019-2025
35 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $1,177 · 2021: $1,490 · 2022: $3,252 · 2023: $904 · 2024: $1,551 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,189.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,052.72 | 2019-2025 | Aveir, Gallant, Triclip |
| Novartis Pharmaceuticals Corporation | $1,340.99 | 2019-2025 | |
| Edwards Lifesciences Corporation | $1,231.54 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $659.71 | 2019-2024 | Xarelto |
| Pfizer INC. | $594.23 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $424.59 | 2022-2024 | Opsumit |
| Boston Scientific Corporation | $417.51 | 2019-2025 | S-Icd System Magnet, Bodyguardian |
| Amgen INC. | $405.77 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $333.26 | 2019-2025 | Farxiga, Wainua |
| Medtronic, INC. | $323.17 | 2023-2025 | Corevalve Evolut R |
| Sanofi-Aventis U.S. LLC | $311.70 | 2019-2023 | |
| Esperion Therapeutics, INC. | $301.37 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.42 | 2019-2025 | Jardiance |
| Bardy Diagnostics, INC. | $290.00 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $277.62 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $170.22 | 2021-2022 | |
| Novo Nordisk INC | $168.37 | 2024-2025 | Ozempic, Wegovy |
| Amarin Pharma, INC. | $151.08 | 2019-2021 | |
| Zoll Respicardia, INC. | $140.38 | 2021 | |
| Baxter Healthcare | $107.57 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $104.99 | 2023-2024 | Inpefa |
| Arbor Pharmaceuticals, INC. | $104.53 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $95.32 | 2022-2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $91.15 | 2019-2025 | Camzyos, Eliquis |
| Vivaquant INC, Dba Rhythm Express | $84.78 | 2024 | Rhythm Express |
| Alnylam Pharmaceuticals INC. | $75.69 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $71.35 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $66.43 | 2019 | |
| Astellas Pharma US INC | $46.08 | 2019-2021 | |
| Medicure Pharma INC. | $41.39 | 2021 | |
| Bridgebio Pharma, INC. | $41.31 | 2025 | Attruby |
| Scpharmaceuticals INC. | $20.62 | 2023 | |
| Biotronik INC. | $18.70 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.49 | 2019 | |
| Allergan, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.